Amgen Inc. (NASDAQ:AMGN) Shares Sold by Ironwood Financial llc

Ironwood Financial llc trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,710 shares of the medical research company’s stock after selling 103 shares during the period. Ironwood Financial llc’s holdings in Amgen were worth $1,840,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Capital International Investors boosted its holdings in shares of Amgen by 547.8% during the 1st quarter. Capital International Investors now owns 7,005,269 shares of the medical research company’s stock worth $1,991,738,000 after purchasing an additional 5,923,915 shares during the last quarter. Vanguard Group Inc. boosted its stake in Amgen by 6.2% during the first quarter. Vanguard Group Inc. now owns 52,088,210 shares of the medical research company’s stock worth $14,809,720,000 after buying an additional 3,045,657 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Amgen by 137.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,381,133 shares of the medical research company’s stock valued at $676,984,000 after buying an additional 1,377,007 shares in the last quarter. Capital Wealth Planning LLC increased its stake in shares of Amgen by 28,684.1% in the 1st quarter. Capital Wealth Planning LLC now owns 833,300 shares of the medical research company’s stock worth $236,924,000 after acquiring an additional 830,405 shares during the last quarter. Finally, Granite Bay Wealth Management LLC raised its holdings in shares of Amgen by 9,058.1% during the 2nd quarter. Granite Bay Wealth Management LLC now owns 756,460 shares of the medical research company’s stock worth $223,897,000 after acquiring an additional 748,200 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Up 0.0 %

Shares of Amgen stock traded up $0.14 on Thursday, reaching $321.77. 127,283 shares of the company were exchanged, compared to its average volume of 2,444,613. The stock’s 50 day moving average price is $326.15 and its 200-day moving average price is $311.56. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The company has a market cap of $172.61 billion, a P/E ratio of 45.95, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). The firm had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company’s revenue was up 20.1% on a year-over-year basis. During the same quarter last year, the firm earned $5.00 EPS. As a group, equities analysts forecast that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were given a dividend of $2.25 per share. The ex-dividend date was Friday, August 16th. This represents a $9.00 annualized dividend and a dividend yield of 2.80%. Amgen’s dividend payout ratio is currently 128.57%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on AMGN shares. Robert W. Baird reissued an “underperform” rating and issued a $215.00 price objective on shares of Amgen in a report on Wednesday, September 25th. Sanford C. Bernstein assumed coverage on shares of Amgen in a report on Thursday. They set an “outperform” rating and a $380.00 price target for the company. Bank of America upped their price objective on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Argus raised their target price on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Finally, Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $320.00 to $335.00 in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $329.48.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.